Chronic obstructive pulmonary disease affects hundreds of millions of people globally, and its acute exacerbations — sudden worsening episodes that accelerate lung function decline and drive hospitalization — have long resisted effective biological intervention. A new Phase III randomized controlled trial published in the New England Journal of Medicine now tests whether blocking the alarmin cytokine IL-33 can change that calculus for high-risk COPD patients.
Tozorakimab is a monoclonal antibody that targets IL-33, an upstream inflammatory signal released by damaged epithelial cells in the airways. By neutralizing IL-33 before it can activate its receptor ST2 on immune and structural cells, the therapy aims to dampen the innate immune cascade that triggers exacerbations — particularly those driven by viral respiratory infections. The NEJM-published trial enrolled patients with moderate-to-severe COPD who remained at elevated exacerbation risk despite standard maintenance therapy, measuring the annualized rate of moderate-to-severe exacerbations as its primary endpoint. Results indicated a meaningful reduction in exacerbation frequency in the tozorakimab arm compared to placebo.
This finding positions tozorakimab within a rapidly evolving field of COPD biologics. Unlike dupilumab — recently approved for eosinophilic COPD — tozorakimab targets an earlier inflammatory checkpoint and may benefit patients regardless of eosinophil count, potentially broadening the treatable population. The IL-33/ST2 axis has attracted growing interest since evidence emerged linking it to post-viral airway inflammation, making this a mechanistically coherent strategy for a population where respiratory viruses are a dominant exacerbation trigger. Key limitations to weigh: the trial population is likely enriched for frequent exacerbators, long-term safety data remain sparse, and the cost-effectiveness relative to existing biologics is unestablished. If the full dataset confirms a robust effect size across biomarker subgroups, this could represent a genuine expansion of treatable COPD phenotypes beyond the eosinophilic niche — an incrementally paradigm-shifting development for pulmonary medicine.